A new study, published in the Journal of Clinical Investigation and funded in part by OCRA, has found that mesothelial cells are a critical factor in ovarian cancer metastasis. High-grade serous ovarian cancer, the most common ovarian cancer subtype, is known to be aggressive, and is associated with the presence of ascites and widespread metastases … Continued
A recent study, funded in part by OCRA, has shed new light on how the most common subtype of ovarian cancer develops and metastasizes, by identifying a key molecule that allows malignancies in the fallopian tube to migrate to the ovaries and continue to grow. High-grade serous ovarian carcinoma (HGSOC) is the most common subtype … Continued
As immunotherapies have seen rising success in treating several other cancers, researchers are hard at work uncovering why immunotherapy for ovarian cancer has, so far, proven ineffective. In a study published in Nature, a research team at Memorial Sloan Kettering Cancer Center set out to identify specific factors that lead to immune evasion in high-grade … Continued
A recent study partly funded by OCRA, and published in the Journal of Clinical Oncology, has shown that frequent aspirin use (defined as more than six times per week for more than six months) is associated with a reduction in ovarian cancer risk. Three members of OCRA’s Scientific Advisory Committee – Dr. Andrew Berchuck (also … Continued
Targeting a specific oncogene associated with the most common type of ovarian cancer may help increase a patient’s immune response to tumors, according to recent findings from researchers at The Wistar Institute and their colleagues at University of Pennsylvania and The University of Colorado Anschutz Medical Campus. An oncogene is a mutated version of a … Continued
The interaction between two partner proteins may promote the growth of the most common ovarian cancer subtype, according to recent findings from OCRA-funded researchers at University of Pennsylvania and Cedars-Sinai Medical Center and their colleagues. The learnings, which were published in Science Signaling, may pave the way for the future development of new targeted therapies. HGSOC … Continued
A therapeutic strategy that targets key tumor proteins shows promise for treating the most common subtype of ovarian cancer, according to a recent study led by OCRA grantee Duygu Ozmadenci, PhD, of the University of California, San Diego Moores Cancer Center. High-grade serous ovarian carcinoma (HGSOC) is the most common subtype of ovarian cancer, with approximately 75% of epithelial ovarian cancers … Continued
OCRA is pleased to announce the recipients of two research prizes, selected by members of our Scientific Advisory Committee for their notable contributions to the field of ovarian cancer research and commitment to future discoveries. Dr. Kathleen Cho Awarded Rosalind Franklin Excellence in Ovarian Cancer Research Prize The Rosalind Franklin Excellence in Ovarian Cancer Research … Continued
New study findings not only reveal where the most common ovarian cancer subtype originates in certain patients, but also point to the future possibility of being able to predict who will get the disease. The research, published in Cell Reports, was led by Clive N. Svendsen, PhD, of Cedars-Sinai Medical Center and OCRA’s Scientific Advisory Committee … Continued
More breakthroughs are on the horizon, as OCRA has awarded grants to 22 dedicated scientists at 15 prestigious medical institutions to enable future ovarian cancer discoveries. With this funding, OCRA grantees aim to answer questions that have vexed the scientific community, building on our collective knowledge and identifying new opportunities for ovarian cancer prevention and … Continued
Dr. Anne van Harten, of the Sidney Kimmel Cancer Center at Thomas Jefferson University in Philadelphia, is a 2021 recipient of OCRA’s Ann and Sol Schreiber Mentored Investigator Award. With her project, “Targeted MDM2 Degradation as a Novel Treatment for Ovarian Cancer,” Dr. van Harten is designing and testing a new compound to target a … Continued
OCRA grantees Ignacio Vázquez-García, PhD and Sohrab Shah, PhD, of Memorial Sloan Kettering Cancer Center, along with colleagues, have found that distinct mutational processes determine the different mechanisms by which certain ovarian cancer tumors are able to evade the immune system and continue to grow. These learnings may lead the way to future immunotherapeutic approaches that can more … Continued
Get email updates about research news, action alerts, and ways to join the fight.
